Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.69 |
| ▸ | GSK3A | P49840 | 8/20 | 0.69 |
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.62 |
| ▸ | CDK2 | P24941 | 5/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497986 | 0.98 | GSK3B (0.69) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4491360 | 0.88 | AAK1 (0.68) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4497932 | 0.88 | HDAC6 (0.66) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4502945 | 0.87 | GSK3B (0.72) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4483953 | 0.87 | GSK3B (0.65) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4499817 | 0.87 | GSK3A (0.91) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4487781 | 0.86 | AAK1 (0.61) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4490775 | 0.86 | AAK1 (0.68) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4485822 | 0.85 | AAK1 (0.72) | GSK3BGSK3AAAK1CDK2PIK3CD | |
| SCHEMBL4492327 | 0.85 | HDAC6 (0.66) | GSK3BGSK3AAAK1CDK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | claimed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | claimed |
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | claimed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | claimed |
| EP-1870405-A1 | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2007-12-26 | — | — | EP | claimed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-1870405-A1 | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | GSK3B 2004/4885GSK3A 1996/4885AAK1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.